118 related articles for article (PubMed ID: 18471157)
41. Adverse drug interactions as a high-risk factor for lethal post-transplant complications in Chinese population.
Yang T; Wu XM; Qiu HQ; Fu DH; Hu JD; Li J; Zheng XY; Luo XF; Yuan XH; Chen RL; Chen ZZ
Clin Transplant; 2013; 27(2):255-60. PubMed ID: 23294039
[TBL] [Abstract][Full Text] [Related]
42. Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction.
van der Elst KC; Brüggemann RJ; Rodgers MG; Alffenaar JW
Transpl Infect Dis; 2012 Aug; 14(4):440-3. PubMed ID: 22316392
[TBL] [Abstract][Full Text] [Related]
43. Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey.
Groll AH; Attarbaschi A; Schuster FR; Herzog N; Grigull L; Dworzak MN; Beutel K; Laws HJ; Lehrnbecher T
J Antimicrob Chemother; 2006 Mar; 57(3):527-35. PubMed ID: 16431856
[TBL] [Abstract][Full Text] [Related]
44. Successful combined antifungal salvage therapy with liposomal amphothericin B and caspofungin for invasive Aspergillus flavus infection in a child following allogeneic bone marrow transplantation.
Kriván G; Sinkó J; Nagy IZ; Goda V; Reményi P; Bátai A; Lueff S; Kapás B; Réti M; Tremmel A; Masszi T
Acta Biomed; 2006; 77 Suppl 2():17-21. PubMed ID: 16918062
[TBL] [Abstract][Full Text] [Related]
45. Caspofungin in the treatment of invasive fungal infections.
Keady S; Thacker M
Intensive Crit Care Nurs; 2006 Feb; 22(1):59-62. PubMed ID: 16006127
[TBL] [Abstract][Full Text] [Related]
46. Safety and interactions of new antifungals in stem cell transplant recipients.
Girmenia C; Iori AP
Expert Opin Drug Saf; 2012 Sep; 11(5):803-18. PubMed ID: 22913714
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of caspofungin therapy in children with invasive fungal infections.
Merlin E; Galambrun C; Ribaud P; Blanc T; Michel G; Auvrignon A; Stéphan JL
Pediatr Infect Dis J; 2006 Dec; 25(12):1186-8. PubMed ID: 17133169
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection.
de Fabritiis P; Spagnoli A; Di Bartolomeo P; Locasciulli A; Cudillo L; Milone G; Busca A; Picardi A; Scimè R; Bonini A; Cupelli L; Chiusolo P; Olivieri A; Santarone S; Poidomani M; Fallani S; Novelli A; Majolino I
Bone Marrow Transplant; 2007 Aug; 40(3):245-9. PubMed ID: 17529996
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients.
Brüggemann RJ; Blijlevens NM; Burger DM; Franke B; Troke PF; Donnelly JP
J Antimicrob Chemother; 2010 Jan; 65(1):107-13. PubMed ID: 19933691
[TBL] [Abstract][Full Text] [Related]
50. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK.
Bruynesteyn K; Gant V; McKenzie C; Pagliuca T; Poynton C; Kumar RN; Jansen JP
Eur J Haematol; 2007 Jun; 78(6):532-9. PubMed ID: 17419744
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics of micafungin in patients undergoing allogeneic hematopoietic stem cell transplantation.
Oshima K; Kanda Y; Kako S; Ohno K; Kishino S; Kurokawa M
Transpl Infect Dis; 2013 Jun; 15(3):323-7. PubMed ID: 23578224
[TBL] [Abstract][Full Text] [Related]
52. Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy.
Kabbara N; Lacroix C; Peffault de Latour R; Socié G; Ghannoum M; Ribaud P
Haematologica; 2008 Apr; 93(4):639-40. PubMed ID: 18379015
[No Abstract] [Full Text] [Related]
53. Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate.
Goodman D; Pamer E; Jakubowski A; Morris C; Sepkowitz K
Clin Infect Dis; 2002 Aug; 35(3):E35-6. PubMed ID: 12115115
[TBL] [Abstract][Full Text] [Related]
54. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial.
DiNubile MJ; Lupinacci RJ; Strohmaier KM; Sable CA; Kartsonis NA
J Crit Care; 2007 Sep; 22(3):237-44. PubMed ID: 17869975
[TBL] [Abstract][Full Text] [Related]
55. Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B.
Krüger WH; Rüssmann B; de Wit M; Kröger N; Renges H; Sobottka I; Zander AR
Acta Haematol; 2005; 113(2):104-8. PubMed ID: 15802888
[TBL] [Abstract][Full Text] [Related]
56. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
[TBL] [Abstract][Full Text] [Related]
57. Retrospective study of the safety of caspofungin in immunocompromised pediatric patients.
Franklin JA; McCormick J; Flynn PM
Pediatr Infect Dis J; 2003 Aug; 22(8):747-9. PubMed ID: 12938676
[No Abstract] [Full Text] [Related]
58. Drug interactions between micafungin at high doses and cyclosporine A in febrile neutropenia patients after allogeneic hematopoietic stem cell transplantation.
Inoue Y; Saito T; Ogawa K; Nishio Y; Kosugi S; Suzuki Y; Kato M; Sakai T; Takahashi M; Miura I
Int J Clin Pharmacol Ther; 2012 Nov; 50(11):831-7. PubMed ID: 22943928
[TBL] [Abstract][Full Text] [Related]
59. Echinocandins: the newest class of antifungals.
Sucher AJ; Chahine EB; Balcer HE
Ann Pharmacother; 2009 Oct; 43(10):1647-57. PubMed ID: 19724014
[TBL] [Abstract][Full Text] [Related]
60. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis.
Cesaro S; Toffolutti T; Messina C; Calore E; Alaggio R; Cusinato R; Pillon M; Zanesco L
Eur J Haematol; 2004 Jul; 73(1):50-5. PubMed ID: 15182338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
